Add BrightSurf on Google Email

Protein identified as a potential biomarker and therapeutic target for aggressive neuroendocrine carcinomas

Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.

Pioneering study indicates a potential treatment for corneal endothelial disease, reducing the need for corneal transplants

A pioneering study published in The American Journal of Pathology reveals the cytoprotective and proregenerative effects of neuropeptide α-MSH in promoting corneal healing after eye injury. The treatment has shown impressive therapeutic potential in reducing the need for corneal transplants.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateJan 2, 2024

Studies help explain why some prostate cancers become resistant to hormone therapy

Two studies led by UCLA researchers reveal how cancer cells use energy to survive and grow, shedding light on why some prostate cancers become resistant to hormone therapy. The findings highlight the importance of considering cell metabolism in developing new cancer treatments, particularly those targeting the androgen receptor.

Long-standing hormone treatment for donated hearts found to be ineffective

A clinical trial by researchers at Washington University School of Medicine found routine thyroid hormone intervention to be ineffective in preserving heart function and increasing organ availability for transplantation. The practice may even cause harm, prompting the authors to recommend halting its use.

SourceWashU Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 29, 2023

Mount Sinai researchers find testosterone hormone therapy for transmasculine individuals is safer than previously thought

Mount Sinai researchers have found that testosterone treatment is safer than previously reported, with a smaller degree of change in hematocrit levels. The study, involving over 6,670 transmasculine patients, suggests that providers can feel more comfortable prescribing testosterone as part of gender-affirming hormone therapy.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalThe Journal of Clinical Endocrinology and Metabolism·DateNov 27, 2023

Anti-rheumatic drugs could prevent thyroid disease

Researchers found that immunomodulatory drugs used to treat rheumatoid arthritis can reduce the risk of autoimmune thyroid diseases. Patients treated with these drugs had a 46% lower risk of developing an autoimmune thyroid disease compared to those without rheumatoid arthritis.

SourceKarolinska Institutet·JournalJournal of Internal Medicine·TypeObservational study·DateNov 22, 2023

Mouse model of gender-affirming testosterone treatment and fertility finds decrease in egg yield but not quality

A mouse model study found that testosterone treatment decreased egg yield without affecting quality, but outcomes improved with a washout period. This research provides evidence to inform fertility care for transgender and gender diverse people who wish to become parents.

SourceMichigan Medicine - University of Michigan·JournalAmerican Journal of Obstetrics and Gynecology·TypeExperimental study·DateNov 7, 2023

Hollings researchers uncover new targets for breast cancers resistant to standard therapies

Researchers at MUSC Hollings Cancer Center have identified new targets for treating breast cancer that has become resistant to hormone therapy and CDK4/6 inhibitors. By understanding the molecular mechanisms of resistance, the team has found potential solutions using epidermal growth factor receptors and PARP inhibitors.

SourceMedical University of South Carolina·JournalNature Communications·DateNov 2, 2023

An updated look at prostate cancer disparities

A new study finds that systemic therapies for advanced prostate cancer are equally effective for Black men as they are for white men, regardless of socioeconomic status. The research suggests that disparities in healthcare can be eliminated with equal access to treatment.

SourceCedars-Sinai Medical Center·JournalJournal of Clinical Oncology·TypeData/statistical analysis·DateOct 27, 2023

First-of-its kind hormone replacement treatment shows promise in patient trials

A new hormone replacement therapy, Pulsatility, has shown promising results in improving symptoms and quality of life for patients with adrenal insufficiency conditions. The treatment, which delivers hydrocortisone in a pulsatile pattern, decreased fatigue by 10% and improved mood and energy levels by 30%.

SourceUniversity of Bristol·JournalJournal of Internal Medicine·TypeRandomized controlled/clinical trial·DateOct 19, 2023

Stemming the tide of antibiotic resistance – researchers shed light on the complexities of hospital wastewater treatment

A multidisciplinary team investigates hospital wastewater samples and demonstrates the effectiveness of photocatalytic treatment in reducing pharmaceutically active compounds and bacteria. The study highlights the challenges posed by antibiotic-resistant bacteria and suggests a promising step towards sustainable wastewater treatment.

SourceSociety of Chemical Industry·JournalJournal of Chemical Technology and Biotechnology·DateSep 27, 2023

Pediatric endocrinologists concerned for safety amid divisive political climate

A new study found pediatric endocrinologists are concerned about threats to their personal safety and the impact of transgender health bans on medical practice. The researchers surveyed 223 pediatric endocrinologists, with 56% providing gender-affirming care, and identified safety concerns, pressures on hospitals, and threats against p...

SourceThe Endocrine Society·JournalJournal of the Endocrine Society·DateSep 19, 2023

Personalized combination treatment turns on an immunometabolic switch to effectively control an aggressive form of prostate cancer

Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.

SourceUniversity of Chicago Medical Center·JournalClinical Cancer Research·DateSep 18, 2023

Groundbreaking research unveils genetic characteristics and improved prognosis of triple negative apocrine carcinoma

Researchers identified distinct genomic characteristics that impact prognosis for patients with triple negative apocrine carcinoma. The study confirmed a five-year disease-free survival rate of 92.2% for these patients, significantly higher than those diagnosed with other types of TNBC.

Researchers uncover NSMF protein’s role in relieving DNA replication stress

Researchers discovered NSMF protein's role in alleviating DNA replication stress by displacing weakly bound RPA proteins and promoting phosphorylation. This mechanism accelerates relief of replication stress, offering a new direction for treating various diseases, including cancer and age-related conditions.